Financhill
Buy
52

RIGL Quote, Financials, Valuation and Earnings

Last price:
$18.88
Seasonality move :
5.85%
Day range:
$18.63 - $19.49
52-week range:
$8.61 - $29.82
Dividend yield:
0%
P/E ratio:
9.12x
P/S ratio:
1.66x
P/B ratio:
18.17x
Volume:
212.5K
Avg. volume:
202.8K
1-year change:
96.26%
Market cap:
$337.4M
Revenue:
$179.3M
EPS (TTM):
$2.07

Analysts' Opinion

  • Consensus Rating
    Rigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $33.74, Rigel Pharmaceuticals has an estimated upside of 78.72% from its current price of $18.88.
  • Price Target Downside
    According to analysts, the lowest downside price target is $20.45 representing 100% downside risk from its current price of $18.88.

Fair Value

  • According to the consensus of 5 analysts, Rigel Pharmaceuticals has 78.72% upside to fair value with a price target of $33.74 per share.

RIGL vs. S&P 500

  • Over the past 5 trading days, Rigel Pharmaceuticals has overperformed the S&P 500 by 0.05% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Rigel Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Rigel Pharmaceuticals has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Rigel Pharmaceuticals reported revenues of $53.3M.

Earnings Growth

  • Rigel Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Rigel Pharmaceuticals reported earnings per share of $0.63.
Enterprise value:
320.1M
EV / Invested capital:
--
Price / LTM sales:
1.66x
EV / EBIT:
6.96x
EV / Revenue:
1.58x
PEG ratio (5yr expected):
--
EV / Free cash flow:
8.99x
Price / Operating cash flow:
9.46x
Enterprise value / EBITDA:
6.61x
Gross Profit (TTM):
$182M
Return On Assets:
25.32%
Net Income Margin (TTM):
18.31%
Return On Equity:
--
Return On Invested Capital:
76.12%
Operating Margin:
23.95%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $129.6M $120.3M $203.1M $29.5M $53.3M
Gross Profit $127M $112.2M $182M $27.5M $48.9M
Operating Income -$40.7M -$14.7M $43.9M -$7M $12.8M
EBITDA -$39.8M -$11M $48.5M -$6M $14M
Diluted EPS -$2.60 -$1.13 $2.07 -$0.47 $0.63
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $196.8M $138.9M $107M $92.5M $146.6M
Total Assets $216M $149.1M $123.6M $126.5M $176M
Current Liabilities $52M $59.2M $45.5M $73.2M $66.6M
Total Liabilities $137.7M $142.3M $147.9M $158.2M $157.4M
Total Equity $78.3M $6.8M -$24.3M -$31.7M $18.6M
Total Debt $19.8M $29.8M $59.5M $59.7M $59.7M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$52.2M -$6.7M $35.6M -$5M -$893K
Cash From Investing $50.9M -$4.8M -$6.7M $313K -$10.6M
Cash From Financing $16.9M -$3.3M -$8.6M -$2.5M $484K
Free Cash Flow -$67.4M -$6.8M $35.6M -$5.2M -$893K
RIGL
Sector
Market Cap
$337.4M
$33.5M
Price % of 52-Week High
63.31%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.97%
1-Year Price Total Return
96.26%
-33.61%
Beta (5-Year)
1.264
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $18.88
200-day SMA
Sell
Level $19.33
Bollinger Bands (100)
Sell
Level 17.94 - 20.82
Chaikin Money Flow
Buy
Level 114.1K
20-day SMA
Sell
Level $19.19
Relative Strength Index (RSI14)
Sell
Level 46.28
ADX Line
Buy
Level 11.76
Williams %R
Neutral
Level -55.1515
50-day SMA
Sell
Level $19.50
MACD (12, 26)
Buy
Level 2.71
25-day Aroon Oscillator
Sell
Level -40
On Balance Volume
Sell
Level -6.8K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-8.6081)
Sell
CA Score (Annual)
Level (-1.831)
Buy
Beneish M-Score (Annual)
Level (-2.3172)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.9046)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Stock Forecast FAQ

In the current month, RIGL has received 1 Buy ratings 4 Hold ratings, and 0 Sell ratings. The RIGL average analyst price target in the past 3 months is $33.74.

  • Where Will Rigel Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Rigel Pharmaceuticals share price will rise to $33.74 per share over the next 12 months.

  • What Do Analysts Say About Rigel Pharmaceuticals?

    Analysts are divided on their view about Rigel Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rigel Pharmaceuticals is a Sell and believe this share price will drop from its current level to $20.45.

  • What Is Rigel Pharmaceuticals's Price Target?

    The price target for Rigel Pharmaceuticals over the next 1-year time period is forecast to be $33.74 according to 5 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is RIGL A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Rigel Pharmaceuticals is a Hold. 4 of 5 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of RIGL?

    You can purchase shares of Rigel Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rigel Pharmaceuticals shares.

  • What Is The Rigel Pharmaceuticals Share Price Today?

    Rigel Pharmaceuticals was last trading at $18.88 per share. This represents the most recent stock quote for Rigel Pharmaceuticals. Yesterday, Rigel Pharmaceuticals closed at $18.88 per share.

  • How To Buy Rigel Pharmaceuticals Stock Online?

    In order to purchase Rigel Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock